Prognostic Factors and Long-term Surgical Outcomes for Exudative Age-related Macular Degeneration with Breakthrough Vitreous Hemorrhage
3
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: We sought to evaluate the long-term outcomes for patients with exudative age-related macular degeneration (AMD)undergoing vitrectomy for breakthrough vitreous hemorrhage and to investigate possible prognostic factors. Methods: Consecutive patients treated at two high-volume referral-based tertiary hospitals between July 2006 and December2019 were retrospectively reviewed. Surgery was performed using the standard three-port vitrectomy. The primary outcomewas the change in best-corrected visual acuity (BCVA) over long-term follow-up, while secondary outcomes includedthe assessment of possible prognostic factors. Results: Among 50 eyes from 50 patients included in this study, 23 (46%) were diagnosed with polypoidal choroidal vasculopathy(PCV) and 27 (54%) were diagnosed with neovascular AMD. Preoperative vision at the time of vitreous hemorrhageonset was 20 / 3,027 (logarithm of the minimum angle of resolution [logMAR], 2.18 ± 0.34). At 12 months after surgery, themean BCVA improved to 20 / 873 (logMAR, 1.64 ± 0.76; p < 0.001). At 24 months, the BCVA was 20 / 853 (logMAR, 1.63 ±0.75; p < 0.001). Univariate analysis revealed that older age (odds ratio [OR], 0.879; p = 0.007] and the presence of submacularhemorrhage (OR, 0.081; p = 0.022) were factors associated with a poor 2-year visual outcome. Multivariable regressionshowed that older age (OR, 0.876; p = 0.026) and neovascular AMD (as compared with PCV) (OR, 0.137; p = 0.014) weresignificant negative factors influencing the 2-year visual outcome. The mean injection interval prior to vitrectomy was 4.53months, which extended to 27.64 months after vitrectomy (p = 0.028). Conclusions: Younger age, the absence of submacular hemorrhage, and PCV type were associated with a favorable 2-yearvisual outcome after vitrectomy for vitreous hemorrhage in patients with exudative AMD. Overall, vitrectomy resulted in improvedvisual acuity and patients showed a decreased need for anti-vascular endothelial growth factor therapy thereafter
Abstract
Purpose: We sought to evaluate the long-term outcomes for patients with exudative age-related macular degeneration (AMD)undergoing vitrectomy for breakthrough vitreous hemorrhage and to investigate possible prognostic factors. Methods: Consecutive patients treated at two high-volume referral-based tertiary hospitals between July 2006 and December2019 were retrospectively reviewed. Surgery was performed using the standard three-port vitrectomy. The primary outcomewas the change in best-corrected visual acuity (BCVA) over long-term follow-up, while secondary outcomes includedthe assessment of possible prognostic factors. Results: Among 50 eyes from 50 patients included in this study, 23 (46%) were diagnosed with polypoidal choroidal vasculopathy(PCV) and 27 (54%) were diagnosed with neovascular AMD. Preoperative vision at the time of vitreous hemorrhageonset was 20 / 3,027 (logarithm of the minimum angle of resolution [logMAR], 2.18 ± 0.34). At 12 months after surgery, themean BCVA improved to 20 / 873 (logMAR, 1.64 ± 0.76; p < 0.001). At 24 months, the BCVA was 20 / 853 (logMAR, 1.63 ±0.75; p < 0.001). Univariate analysis revealed that older age (odds ratio [OR], 0.879; p = 0.007] and the presence of submacularhemorrhage (OR, 0.081; p = 0.022) were factors associated with a poor 2-year visual outcome. Multivariable regressionshowed that older age (OR, 0.876; p = 0.026) and neovascular AMD (as compared with PCV) (OR, 0.137; p = 0.014) weresignificant negative factors influencing the 2-year visual outcome. The mean injection interval prior to vitrectomy was 4.53months, which extended to 27.64 months after vitrectomy (p = 0.028). Conclusions: Younger age, the absence of submacular hemorrhage, and PCV type were associated with a favorable 2-yearvisual outcome after vitrectomy for vitreous hemorrhage in patients with exudative AMD. Overall, vitrectomy resulted in improvedvisual acuity and patients showed a decreased need for anti-vascular endothelial growth factor therapy thereafter
참고문헌 (23)
- Wong WL, "Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040 : a systematic review and meta-analysis", Lancet Glob Health, 2, pp.e106~e116 (2014)
- Congdon N, "Causes and prevalence of visual impairment among adults in the United States", Arch Ophthalmol, 122, pp.477~485 (2004)
- Googe JM, "Vitreous hemorrhage secondary to age-related macular degeneration", Surv Ophthalmol, 32, pp.123~130 (1987)
- Azzolini C, "Age-related macular degeneration and vitreous hemorrhage", Eur J Ophthalmol, 1, pp.142~147 (1991)
- Roufail E, "Combined cataract surgery and vitrectomy for vitreous haemorrhage secondary to age-related macular degeneration", Clin Exp Ophthalmol, 36, pp.36~38 (2008)
- Kang HG, "Long-term visual outcomes for treatment of submacular haemorrhage secondary to polypoidal choroidal vasculopathy", Clin Exp Ophthalmol, 46, pp.916~925 (2018)
- Li ZX, "Long-term observation of vitrectomy without subretinal hemorrhage management for massive vitreous hemorrhage secondary to polypoidal choroidal vasculopathy", Int J Ophthalmol, 12, pp.1859~1864 (2019)
- Lin HC, "Visual outcomes of vitrectomy for polypoidal choroidal vasculopathy-related breakthrough vitreous haemorrhage", Eye(Lond), 28, pp.797~806 (2014)
- Choi EY, "Impact of antibiotic resistance of pathogens and early vitrectomy on the prognosis of infectious endophthalmitis : a 10-year retrospective study", Graefes Arch Clin Exp Ophthalmol, 257, pp.805~813 (2019)
- Muda R, "Endogenous endophthalmitis : a 9-year retrospective study at a tertiary referral hospital in Malaysia", J Ophthalmic Inflamm Infect, 8, pp.14~ (2018)
- Hasegawa T, "Prognostic factors of vitreous hemorrhage secondary to exudative age-related macular degeneration", Am J Ophthalmol, 149, pp.322~329 (2010)
- Ehrlich R, "Age-related macular degeneration and the aging eye", Clin Interv Aging, 3, pp.473~482 (2008)
- Friedman E, "A hemodynamic model of the pathogenesis of age-related macular degeneration", Am J Ophthalmol, 124, pp.677~682 (1997)
- Fine SL, "Age-related macular degeneration", N Engl J Med, 342, pp.483~492 (2000)
- 장영석, "Development of Submacular Hemorrhage in Neovascular Age-related Macular Degeneration: Influence on Visual Prognosis in a Clinical Setting", Korean Journal of Ophthalmology, 32(5), pp.361~368 (2018), 대한안과학회[DOI]
- Cho JH, "Incidence rate of massive submacular hemorrhage and its risk factors in polypoidal choroidal vasculopathy", Am J Ophthalmol, 169, pp.79~88 (2016)
- Stanescu-Segall D, "Submacular hemorrhage in neovascular age-related macular degeneration : a synthesis of the literature", Surv Ophthalmol, 61, pp.18~32 (2016)
- Chaudhry NA, "Combined cataract surgery and vitrectomy for breakthrough vitreous hemorrhage from age-related macular degeneration", Ophthalmic Surg Lasers, 33, pp.16~18 (2002)
- "Age-related macular degeneration: preferred practice pattern guideline" (2014)[URL]
- Agarwal A, "Management of neovascular age-related macular degeneration : current state-of-the-art care for optimizing visual outcomes and therapies in development", Clin Ophthalmol, 9, pp.1001~1015 (2015)
- Lim LS, "Retinal vessel oxygen saturation increases after vitrectomy", Invest Ophthalmol Vis Sci, 55, pp.3851~3856 (2014)
- Baek J, "Disease activity after development of large subretinal hemorrhage in polypoidal choroidal vasculopathy", Retina, 38, pp.1993~2000 (2018)
- Wong CW, "Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians", Prog Retin Eye Res, 53, pp.107~139 (2016)